Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (1049)	11/13/1998 10:37:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 1722

Curtis, I think MTC has a very good chance of getting FDA approval for Celebrex (the research studies presented so far do not indicate problems with the drug in its clinical trials). The trials speak for themselves. According to BigKNY3, our resident Pfizer expert at the Pfizer thread, to date, every NDA that has been granted expedited review by the FDA has been approved within the 6 month time frame. Their sales force doesn't much matter, since PFE is marketing the drug for them. In their third-quarters earnings report in October, Pfizer indicated that they had spent close to $100 million to hire 1,100 extra salespeople in advance of the Celebrex launch. Anthony